Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

november-december, 2024
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Quality / GMP

Piramal Pharma gets zero observations from US FDA for Riverview, Michigan facility

Piramal Pharma gets zero observations from US FDA for Riverview, Michigan facility

The US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Riverview (Michigan, USA) facility from October 31, 2022 to November 4, 2022.

The inspection was completed successfully with Zero Form - 483 observations.

The company remains committed to maintaining the highest standards of compliance.
Read more on:
GMP Piramal Pharma US FDA
More news about: quality / gmp | Published by Sudeep Soparkar | November - 11 - 2022 | 391

Last news about this category

LGM Pharma Expands Analytical Testing Services with New Services LGM Pharma Expands Analytical Testing Services with New Services
Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices
eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China
Aurisco's Manufacturing Site in China Clears FDA Inspection Aurisco's Manufacturing Site in China Clears FDA Inspection
Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC) Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
Concord Biotech Limited receives EIR for Unit III Concord Biotech Limited receives EIR for Unit III
Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China
Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy